CD133 epitope vaccine with gp96 as adjuvant elicits an antitumor T cell response against leukemia.

Shuo Wang; Hongxia Fan; Yang LI; Huaguo Zheng; Xin LI; Changfei LI; Lizhao Chen; Ying JU; Songdong Meng

Return

CD133 epitope vaccine with gp96 as adjuvant elicits an antitumor T cell response against leukemia.

Author: Shuo WANG ¹ ; Hongxia FAN ² ; Yang LI ³ ; Huaguo ZHENG ³ ; Xin LI ³ ; Changfei LI ³ ; Lizhao CHEN ³ ; Ying JU ³ ; Songdong MENG ³
Author Information

1. College of Life Sciences, Hebei University, Baoding 071002, Hebei, China.
2. School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
3. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Publication Type:Journal Article
Keywords: CD133; CTL; epitope; gp96; leukemia
From: Chinese Journal of Biotechnology 2017;33(6):1006-1017
CountryChina
Language:Chinese
Abstract: Cancer stem cells are currently under intensive investigation due to their capabilities for tumor initiation, self-renewal, and resistance to chemotherapy. CD133 is implicated in stemness and the malignancy of tumor cells. Here, we explored heat shock protein gp96 adjuvanted CD133 epitope vaccine against leukemia. We screened and identified three H2-Kd-restricted cytotoxic T lymphocyte (CTL) epitopes derived from CD133, CD133₄₁₉₋₄₂₈, CD133₇₀₂₋₇₁₀ and CD133₇₆₀₋₇₆₉. The immunogenicity and antitumor activity of the epitope vaccine using heat shock protein gp96 as adjuvant were further determined in CD133⁺ leukemia xenograft mice. Finally, we demonstrate that adoptive transfer of epitope-specific CTLs led to suppression of leukemia growth. Our data therefore provide the basis for designing a CD133 epitope vaccine to activate specific CTLs against CD133⁺ leukemia and other cancers.